Last Updated: August 10, 2026

Litigation Details for Cisco Systems Inc v. Arista Networks, Inc. (N.D. Cal. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cisco Systems Inc v. Arista Networks, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Cisco Systems Inc v. Arista Networks, Inc. (5:14-cv-05344): Litigation Summary, Procedural Posture, and Claim/Strategy Implications

Last updated: June 25, 2026

Executive summary

  • Case: Cisco Systems Inc. v. Arista Networks Inc., 5:14-cv-05344 (district court filing).
  • Core issue for analysis: A patent IP dispute between Cisco and Arista, litigated through early claim constructions and dispositive motions typical of U.S. patent cases.
  • Actionable takeaway: The litigation outcome determines (i) which asserted claims are narrowed or invalidated, (ii) whether Cisco obtained enforceable exclusion or damages, and (iii) whether Arista can rely on design-around freedom-to-operate positions for relevant switching/routing features.
  • Limitation: A complete, accurate litigation summary requires specific docket facts (asserted patents, key claim terms, claim construction results, infringement/noninfringement rulings, summary judgment, trial disposition, and any appeal). Those facts are not present in the prompt.

Cisco v. Arista 5:14-cv-05344: What patents and claims were asserted?

Answer (needed for completeness): Not provided in the prompt.

Which patent numbers drive the case outcome?

A litigation analysis depends on the asserted patent set and claim scope. Without patent identifiers and claim lists, it is not possible to:

  • map asserted features to product functionality,
  • evaluate claim construction impact,
  • quantify exposure by claim category (system, method, apparatus),
  • or assess comparative strength across asserted patents.

What claim terms were the litigation center of gravity?

Patent litigation strategy usually turns on a small number of construed terms (for example, packet handling, forwarding behavior, topology control, routing/encapsulation, synchronization, or queueing). Without the claim construction record, no defensible analysis can be provided.

What was the procedural history in Cisco v. Arista 5:14-cv-05344?

Answer (needed for completeness): Not provided in the prompt.

A proper procedural summary requires, at minimum:

  • complaint filing date and jurisdiction,
  • amended complaints and added/removed patents,
  • Markman schedule and claim construction rulings,
  • summary judgment milestones (infringement, invalidity, enforceability),
  • trial dates and verdict (or dismissal/settlement),
  • post-trial motions,
  • appeal docket status (if any).

Without those items, the case cannot be summarized accurately.

When did claim construction happen and how did it affect infringement and invalidity?

Answer (needed for completeness): Not provided in the prompt.

How do Markman rulings change claim scope in Ethernet/switching disputes?

Claim construction typically affects whether accused Arista features fall inside or outside the “must-have” limitations. A credible analysis must connect:

  • construed terms to accused structures/processes, and
  • construed terms to prior art or invalidity arguments.

No docket or order content is included in the prompt.

What did the court decide on summary judgment in Cisco v. Arista 5:14-cv-05344?

Answer (needed for completeness): Not provided in the prompt.

A summary judgment disposition can reshape the case in three principal ways:

  1. grant noninfringement on one or more asserted claims,
  2. find invalidity for anticipation/obviousness,
  3. narrow damages theories or exclude categories of proof.

Without the summary judgment orders, no accurate outcome can be stated.

Was there a trial verdict or settlement in Cisco v. Arista 5:14-cv-05344?

Answer (needed for completeness): Not provided in the prompt.

If trial occurred, what were the outcomes by patent and by claim?

A litigation analysis should include:

  • verdict (infringement/invalidity) by asserted patent,
  • jury findings on willfulness (if alleged),
  • damages calculation method accepted or rejected,
  • injunctive relief request disposition (if any).

No outcome data is available in the prompt.

If settled, what terms matter for future freedom-to-operate?

Settlement terms drive:

  • ongoing license scope,
  • design-around obligations,
  • dismissal with/without prejudice,
  • covenant not to sue for specific products/features,
  • ongoing royalties or payment structures.

No settlement terms appear in the prompt.

Which issues are most likely to be appeal-worthy in Cisco v. Arista 5:14-cv-05344?

Answer (needed for completeness): Not provided in the prompt.

Appeal candidates in patent cases typically include:

  • claim construction errors (reviewed de novo for ultimate meaning),
  • sufficiency of evidence on infringement or invalidity,
  • admissibility/exclusion of expert testimony,
  • legal standards for willfulness, damages, or inequitable conduct.

A meaningful appellate-risk analysis must cite specific disputed rulings.

How strong is Cisco’s patent estate in this case versus Arista’s defenses?

Answer (needed for completeness): Not provided in the prompt.

A defensible “strength” comparison requires:

  • which patents survived dispositive motions,
  • prior-art references used and their dates,
  • whether invalidity was sustained on anticipation or obviousness,
  • whether infringement was found on a full-claim basis.

None of that information is provided.

What generic or product design-around risks would follow from this litigation outcome?

Answer (needed for completeness): Not provided in the prompt.

In networking IP cases, “design-around risk” depends on:

  • which claim limitations are enforced after claim construction,
  • whether the decision is broad (covers standard feature set) or narrow (specific vendor implementation),
  • whether the accused product category is implicated or only particular SKUs.

No court findings are included in the prompt.

Key procedural and litigation artifacts to capture (for decision-making)

Answer (needed for completeness): Not provided in the prompt.

For high-stakes business and R&D decisions, the following docket artifacts are required to do a correct analysis:

  • complaint and amended complaint (asserted patents, parties, product descriptions),
  • claim construction orders (Markman),
  • infringement and invalidity summary judgment orders,
  • Daubert orders (expert testimony),
  • jury verdict or dismissal order,
  • final judgment and any injunction or licensing/covenant terms,
  • appeal briefs and opinions (if applicable).

Those artifacts are not supplied.

Key Takeaways

  • No litigation-specific facts (asserted patents, rulings, verdict/settlement, or procedural timeline) are included in the prompt, so an accurate litigation summary cannot be produced.
  • A correct high-information-density analysis must be grounded in docket orders and the asserted-claims map to accused Arista products.
  • Without those records, any narrative would be speculative and not suitable for litigation, licensing, or investment decision-making.

FAQs

  1. What is the docket status of 5:14-cv-05344 (pending, judgment entered, or dismissed)?
  2. Which specific Cisco patents were asserted in Cisco v. Arista (5:14-cv-05344)?
  3. What claim terms did the court construe, and how did those constructions map to Arista products?
  4. Did Arista win summary judgment on invalidity or noninfringement, and for which asserted claims?
  5. Was there an appeal from any final judgment or post-trial order in 5:14-cv-05344?

References

  1. Not available from the provided input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.